Details der Publikation - This study is to determine the efficacy and safety of Two Dose Levels of Plitidepsin compared with the group of control for patients requiring hospitalization due to COVID-19.

This study is to determine the efficacy and safety of Two Dose Levels of Plitidepsin compared with the group of control for patients requiring hospitalization due to COVID-19. : A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management of Moderate COVID-19 Infection - APL-D-003-20

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 06. Dez. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: moderate COVID-19 infection MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-11-2021, Last updated: 2022-11-24

ICTRP ID:	EUCTR2020-005951-19-ES APL-D-003-20 2020-005951-19-FR

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG008081476

Internformat


LEADER	01000caa a22002652 4500
001	CTG008081476
003	DE-627
005	20230425170335.0
007	cr uuu---uuuuu
008	211222s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG008081476
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-005951-19-ES
035			\|a (UBBS_Klinische_Studien_WHO)APL-D-003-20
035			\|a (UBBS_Klinische_Studien_WHO)2020-005951-19-FR
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a This study is to determine the efficacy and safety of Two Dose Levels of Plitidepsin compared with the group of control for patients requiring hospitalization due to COVID-19. \|b A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management of Moderate COVID-19 Infection - APL-D-003-20
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-11-2021, Last updated: 2022-11-24
650		4	\|a Medical Condition: moderate COVID-19 infection MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 06. Dez.
773	1	8	\|g year:2021 \|g day:06 \|g month:12
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005951-19 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 06 \|c 12

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände